cagrilintide semaglutide cagrisema phase 3 results 2024 2025 obesity Incretin-based therapies for the treatment of obesity-related diseases Weight Loss Efficacy of Cagrilintide – Novo Nordisk's next-gen obesity drug

Esther Lyuh

The Injection (Subcutaneous) - Dosing: Once weekly - Bioavailability: ~100% (bypasses GI tract) - Weight loss in trials: Up to 22% at 36 weeks - Best for: Patients seeking maximum efficacy, comfortable with self-injection The Pill (Oral) - Dosing: Once daily (taken on an empty stomach, similar to Rybelsus) - Bioavailability: Lower than SC (relies on SNAC absorption technology) - Weight loss in trials: Up to 13.1% at 12 weeks (Phase 1 short duration) - Best for: Injection-averse patients, early treatment, maintenance, broader access The oral formulation will almost certainly deliver less weight loss than the subcutaneous version at equivalent treatment durations

doi: 10.1152/physiol.00031.2016 75

So over time, as we see more approvals being added to the labels of these drugs, I think there's a good chance that the insurance companies will have to offer coverage for these other indications. Does Medicaid cover Zepbound

Initially store the solution at room temperature away from light, then refrigerate it